Q-omics provides the consensus-scored SNORA13 profile across patient tissues and cancer cell-line models. SNORA13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SNORA13 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, SNORA13 RNA expression shows 12,924 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, LIHC, and UVM as cancer lineages where SNORA13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA13 survival associations across molecular data types. SNORA13 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA13 RNA expression–survival associations across cancer types. High SNORA13 expression shows unfavorable associations in THCA, ACC, LUAD, STAD, KICH and COAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for SNORA13 RNA expression.
This table summarizes SNORA13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA13 shows higher tumor expression in LIHC, CHOL, COAD, KIRC, BLCA and READ. The LIHC box plot shows higher SNORA13 RNA expression in tumor versus normal tissue (log2 FC = +0.459, t-test p < 0.001).
This table shows molecular features associated with SNORA13 in patient tissues and cancer cell lines. In patient samples, SNORA13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
